Aimmune Therapeutics' (NASDAQ: AIMT) share price has gained 11% over the past month as the company waits for the Food and Drug Administration to issue an approval decision on its very first drug, one that represents the theme of its three-drug pipeline: treatments to address food allergies.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,